SavedAdd your journal

Journals / Eurasian Journal of Medicine and Oncology / 2019 / Cilt: 3 - Sayı: 2

Cannabinoids/Endocannabinoids as Possible Antineoplastic Therapy in Comparisson to Cancer Pharmacological Treatments Used Today: Narrative Review

Fabio Mayorga NİNO
Nelson Camilo Gutierrez ALVARADO
Pages
77–91
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It is important to study more deeply chronopharmacological aspects of cannabinoids/endocannabinoids in cancer therapy, although some is known today.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cancer is a complex pathophysiological condition that produces an important number of death around the world.
📊
Key Findings & Data:Many studies have shown, since 1975, that both phytocannabinoids Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) offer an antioneoplastic activity.
💡
Conclusion & Impact:It is important to study more deeply chronopharmacological aspects of cannabinoids/endocannabinoids in cancer therapy, although some is known today.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Cancer is a complex pathophysiological condition that produces an important number of death around the world. At present, there are different ways to treat cancer: chemotherapy, radiotherapy and surgery. Cancer chemotherapy used today in many cases is effective, but it is very toxic too. The endocannabinoid system is implicated in a variety of physiological and pathological processes, including cancer. Many studies have shown, since 1975, that both phytocannabinoids Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) offer an antioneoplastic activity. Latter, other researchers have displayed that endocannabinoids as anandamide (ANA) and 2-arachidonoylglycerol (2-AG) also present the same potential activity. Phytocannabinoids and endocannabinoids act through CB1 and CB2 receptors to produce that effect. However, THC -the main phytocannabinoid presenting anticancer action- as well as anandamide employed in pharmacological doses, produce important phycotropic effects, but these cannabinoid compounds do not produce major adverse reactions like conventional antineoplastic drugs. On this basis, scientists have to develop analogs or derivatives of cannabinoids/endocannabinoids that cannot induce psychotropic effects. It is important to study more deeply chronopharmacological aspects of cannabinoids/endocannabinoids in cancer therapy, although some is known today.

🔖

Cite This Article

NİNO, F. M., ALVARADO, N. C. G. (2019). Cannabinoids/Endocannabinoids as Possible Antineoplastic Therapy in Comparisson to Cancer Pharmacological Treatments Used Today: Narrative Review. Eurasian Journal of Medicine and Oncology, Cilt: 3 - Sayı: 2, 77–91. https://ajindex.com/articles/125550

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Hermanson DJ, Marnett LJ. Cannabinoids, endocannabinoids, and cancer. Cancer Metastasis Rev 2011;30:599–612
  2. Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA. Antineoplastic activity of cannabinoids. J Natl Cancer Inst 1975;55:597–602
  3. Burstein S, Salmonsen R. Acylamido analogs of endocannabinoids selectively inhibit cancer cell proliferation. Bioorg Med Chem 2008;16:9644–51
  4. Vaughn LK, Denning G, Stuhr KL, de Wit H, Hill MN, Hillard CJ. Endocannabinoid signalling: has it got rhythm? Br J Pharmacol 2010;160:530–43
  5. Bifulco M, Di Marzo V. Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med 2002;8:547–50
  6. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561–4
  7. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61–5
  8. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946–9
  9. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR,et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50:83–90
  10. Farrell EK, Merkler DJ. Biosynthesis, degradation and pharmacological importance of the fatty acid amides. Drug Discov Today 2008;13:558–68
  11. Iannotti FA, Di Marzo V, Petrosino S. Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. Prog Lipid Res 2016;62:107–28
  12. Wang J, Ueda N. Biology of endocannabinoid synthesis system. Prostaglandins Other Lipid Mediat 2009;89:112–9
  13. Guindon J, Hohmann AG. The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol 2011;163:1447–63
  14. Svízenská I, Dubový P, Sulcová A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review. Pharmacol Biochem Behav 2008;90:501–11
  15. Flygare J, Sander B. The endocannabinoid system in cancerpotential therapeutic target? Semin Cancer Biol 2008;18:176– 89
  16. Mayorga NF, CÁRDENAS RHS. Endocannabinoids: A therapeutic option to cancer treatment. [Article in Spanish] Vitae 2009;16:259–67
  17. Taylor AH, Amoako AA, Bambang K, Karasu T, Gebeh A, Lam PM, et